216 related articles for article (PubMed ID: 18094400)
1. Src continues aging: current and future clinical directions.
Kopetz S; Shah AN; Gallick GE
Clin Cancer Res; 2007 Dec; 13(24):7232-6. PubMed ID: 18094400
[TBL] [Abstract][Full Text] [Related]
2. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
Edwards J
Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
[TBL] [Abstract][Full Text] [Related]
3. Src, chemoresistance and epithelial to mesenchymal transition: are they related?
Shah AN; Gallick GE
Anticancer Drugs; 2007 Apr; 18(4):371-5. PubMed ID: 17351389
[TBL] [Abstract][Full Text] [Related]
4. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.
Mayer EL; Krop IE
Clin Cancer Res; 2010 Jul; 16(14):3526-32. PubMed ID: 20634194
[TBL] [Abstract][Full Text] [Related]
5. Issues and progress with protein kinase inhibitors for cancer treatment.
Dancey J; Sausville EA
Nat Rev Drug Discov; 2003 Apr; 2(4):296-313. PubMed ID: 12669029
[TBL] [Abstract][Full Text] [Related]
6. The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors.
Alvarez RH; Kantarjian HM; Cortes JE
Cancer; 2006 Oct; 107(8):1918-29. PubMed ID: 16986126
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors in lymphoma and solid malignancies.
Rasheed W; Bishton M; Johnstone RW; Prince HM
Expert Rev Anticancer Ther; 2008 Mar; 8(3):413-32. PubMed ID: 18366289
[TBL] [Abstract][Full Text] [Related]
8. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
Toschi L; Jänne PA
Clin Cancer Res; 2008 Oct; 14(19):5941-6. PubMed ID: 18829470
[TBL] [Abstract][Full Text] [Related]
9. Rational combinations using HDAC inhibitors.
Bots M; Johnstone RW
Clin Cancer Res; 2009 Jun; 15(12):3970-7. PubMed ID: 19509171
[TBL] [Abstract][Full Text] [Related]
10. Src inhibitors in lung cancer: current status and future directions.
Rothschild SI; Gautschi O; Haura EB; Johnson FM
Clin Lung Cancer; 2010 Jul; 11(4):238-42. PubMed ID: 20630825
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
12. Development of Src tyrosine kinase substrate binding site inhibitors.
Ye G; Tiwari R; Parang K
Curr Opin Investig Drugs; 2008 Jun; 9(6):605-13. PubMed ID: 18516760
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
Ischenko I; Camaj P; Seeliger H; Kleespies A; Guba M; De Toni EN; Schwarz B; Graeb C; Eichhorn ME; Jauch KW; Bruns CJ
Oncogene; 2008 Dec; 27(57):7212-22. PubMed ID: 18794807
[TBL] [Abstract][Full Text] [Related]
14. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on farnesyl transferase inhibitors in cancer therapy.
Mazieres J; Pradines A; Favre G
Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
[TBL] [Abstract][Full Text] [Related]
16. SRC as a potential therapeutic target in solid tumor oncology.
Gallick GE
Clin Adv Hematol Oncol; 2004 Jul; 2(7):435-7. PubMed ID: 16163218
[No Abstract] [Full Text] [Related]
17. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.
Dal Lago L; D'Hondt V; Awada A
Oncologist; 2008 Aug; 13(8):845-58. PubMed ID: 18695262
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Carew JS; Giles FJ; Nawrocki ST
Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
[TBL] [Abstract][Full Text] [Related]
19. Targeting protein kinases in cancer therapy: a success?
Pearson MA; Fabbro D
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1113-24. PubMed ID: 15606337
[TBL] [Abstract][Full Text] [Related]
20. Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?
de Jonge MJ; Verweij J
Eur J Cancer; 2006 Jul; 42(10):1351-6. PubMed ID: 16740386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
